Brief: AIM Provides Summary Of Ampligen Data Supporting Synergistic Potential With Checkpoint Blockade Therapies
21/04/2022 13:17
April 21 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH PROVIDES SUMMARY OF AMPLIGEN® DATA
SUPPORTING
SYNERGISTIC POTENTIAL WITH CHECKPOINT BLOCKADE THERAPIES
* AIM IMMUNOTECH - AMPLIGEN HAS DEMONSTRATED IN PRE-CLINICAL
AND
CLINICAL STUDIES POTENTIAL TO ENHANCE EFFICACY OF PD-1 AND/OR
PD-L1 CHECKPOINT INHIBITORS
* AIM IMMUNOTECH INC - AMPLIGEN'S ANTI-TUMOR POTENTIAL IS
DEMONSTRATED WITH CHECKPOINT BLOCKADE THERAPIES IN HUMAN
CLINICAL STUDIES
Source text for Eikon: ID:nGNE2JYfhG
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential